News Release Details

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 26, 2024 at 8:00 AM EDT

MASON, Ohio--(BUSINESS WIRE)--Mar. 26, 2024-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.

AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 1:30 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X (formerly Twitter) @AtriCure.

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334

Marissa Bych
Gilmartin Group
Investor Relations

Source: AtriCure, Inc.